Annexon, Inc.

Annexon, Inc.verified

ANNX

Price:

$7.1

Market Cap:

$750.14M

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developin...[Read more]

Industry

Biotechnology

IPO Date

2020-07-24

Stock Exchange

NASDAQ

Ticker

ANNX

The Enterprise Value as of September 2024 (TTM) for Annexon, Inc. (ANNX) is 623.04M

According to Annexon, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 623.04M. This represents a change of 70.73% compared to the average of 364.94M of the last 4 quarters.

Annexon, Inc. (ANNX) Historical Enterprise Value (quarterly & annually)

How has ANNX Enterprise Value performed in the past?

The mean historical Enterprise Value of Annexon, Inc. over the last ten years is 358.20M. The current 623.04M Enterprise Value has changed 17.29% with respect to the historical average. Over the past ten years (40 quarters), ANNX's Enterprise Value was at its highest in in the March 2021 quarter at 855.79M. The Enterprise Value was at its lowest in in the December 2018 quarter at -31362680.00.

Quarterly (TTM)
Annual

Average

358.20M

Median

266.44M

Minimum

149.80M

Maximum

724.81M

Annexon, Inc. (ANNX) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Annexon, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 156.40%

Maximum Annual Enterprise Value = 724.81M

Minimum Annual Increase = -75.43%

Minimum Annual Enterprise Value = 149.80M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
2023149.80M-14.64%
2022175.50M-56.12%
2021400.00M156.40%
2020156.00M-75.43%
2019634.88M138.28%
2018266.44M-63.24%

Annexon, Inc. (ANNX) Average Enterprise Value

How has ANNX Enterprise Value performed in the past?

The current Enterprise Value of Annexon, Inc. (ANNX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

241.77M

5-year avg

303.24M

10-year avg

358.20M

Annexon, Inc. (ANNX) Enterprise Value vs. Peers

How is ANNX’s Enterprise Value compared to its peers?

Annexon, Inc.’s Enterprise Value is greater than Immix Biopharma, Inc. (27.90M), greater than CNS Pharmaceuticals, Inc. (3.41M), greater than Hepion Pharmaceuticals, Inc. (2.21M), greater than Freeline Therapeutics Holdings plc (2.82M), greater than AVROBIO, Inc. (-85302404.00), less than Day One Biopharmaceuticals, Inc. (970.00M), greater than Acumen Pharmaceuticals, Inc. (114.06M), greater than X4 Pharmaceuticals, Inc. (50.70M), greater than Inozyme Pharma, Inc. (406.63M), less than VectivBio Holding AG (848.58M), less than IVERIC bio, Inc. (5.14B), less than Blueprint Medicines Corporation (6.13B), greater than Amylyx Pharmaceuticals, Inc. (108.90M), less than Karuna Therapeutics, Inc. (12.43B), less than Arcus Biosciences, Inc. (1.41B), less than Cullinan Oncology, Inc. (863.46M), less than Structure Therapeutics Inc. (1.93B), less than Relay Therapeutics, Inc. (1.24B), greater than Zura Bio Limited (40.51M), less than Icosavax, Inc. (713.87M), greater than IN8bio, Inc. (10.13M), greater than Wave Life Sciences Ltd. (613.37M),

Build a custom stock screener for Annexon, Inc. (ANNX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Annexon, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Annexon, Inc. (ANNX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Annexon, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Annexon, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Annexon, Inc. (ANNX)?

What is the 3-year average Enterprise Value for Annexon, Inc. (ANNX)?

What is the 5-year average Enterprise Value for Annexon, Inc. (ANNX)?

How does the current Enterprise Value for Annexon, Inc. (ANNX) compare to its historical average?